Stock overview
Windward Bio Group AG Common Shares
WWB
Windward Bio Group AG is a clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases, including asthma, COPD, and atopic dermatitis. Its flagship program is WIN378, a potentially novel, long-acting, anti-TSLP monoclonal antibody. The pipeline also includes WIN027, a clinical-stage, long-acting anti-TSLPxIL-13 bi-specific, which has therapeutic application across immunological diseases.
Open XNAS
Fundamentals
Key company ratios and reported financial statements.
Key ratios
No ratio data was found for WWB.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.
No quarterly income statement data was found for WWB.
Recent news
Company coverage with links to the original publishers.
No recent company news found.
Dividends
Declared distributions and recorded event dates. Forecasts are not shown.
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.
No stock split records found.